CN102015691B - 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 - Google Patents
作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 Download PDFInfo
- Publication number
- CN102015691B CN102015691B CN200980115503.0A CN200980115503A CN102015691B CN 102015691 B CN102015691 B CN 102015691B CN 200980115503 A CN200980115503 A CN 200980115503A CN 102015691 B CN102015691 B CN 102015691B
- Authority
- CN
- China
- Prior art keywords
- pyridin
- imidazo
- ylamino
- cyclohexanol
- furan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08155405 | 2008-04-29 | ||
| EP08155405.7 | 2008-04-29 | ||
| PCT/EP2009/055066 WO2009133070A1 (en) | 2008-04-29 | 2009-04-27 | Imidazo-pyridine derivatives as activin-like receptor kinase (alk4 or alk5) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102015691A CN102015691A (zh) | 2011-04-13 |
| CN102015691B true CN102015691B (zh) | 2014-01-08 |
Family
ID=40043988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980115503.0A Expired - Fee Related CN102015691B (zh) | 2008-04-29 | 2009-04-27 | 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9079897B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2307402B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5507543B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100130226A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102015691B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009242145B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0911490A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2722131A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201001687A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2399175T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010011867A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2307402T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2307402E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009133070A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2531500B1 (en) | 2010-02-05 | 2018-01-24 | Merck Patent GmbH | Hetaryl-[1,8]naphthyridine derivatives |
| BR112012019561A2 (pt) | 2010-02-22 | 2019-09-24 | Merck Patent Gmbh | hetarilamino naftiridinas |
| WO2011146287A1 (en) | 2010-05-20 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5 |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| ES2962147T3 (es) | 2010-11-08 | 2024-03-15 | Sk Chemicals Co Ltd | Resina de ácido poliláctico, procedimiento de preparación de la misma, y película de embalaje que comprende la misma |
| US20140088174A1 (en) * | 2011-04-05 | 2014-03-27 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Compounds and methods for altering activin receptor-like kinase signaling |
| CN105431148A (zh) | 2013-03-07 | 2016-03-23 | 加利菲亚生物公司 | 混合谱系激酶抑制剂及治疗方法 |
| EP3283475B1 (en) * | 2015-04-16 | 2019-10-16 | Merck Patent GmbH | 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives |
| HK1257171A1 (zh) * | 2015-09-23 | 2019-10-18 | Dana Farber Cancer Institute, Inc. | 间变性淋巴瘤激酶(alk)和丝氨酸富集蛋白激酶 (sppk)的抑制剂及其使用方法 |
| RU2642456C2 (ru) * | 2016-06-29 | 2018-01-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ярославский государственный университет им. П.Г. Демидова" | Способ получения N-арилзамещенных 3H-имидазо[4,5-b]пиридинов |
| US11466003B2 (en) | 2016-07-29 | 2022-10-11 | Shanghai Yingli Pharmaceutical Co., Ltd | Nitrogenous heterocyclic aromatic compound, preparation method therefor, pharmaceutical composition thereof, and application thereof |
| CN106831770A (zh) * | 2017-03-13 | 2017-06-13 | 牡丹江医学院 | 一种药物组合物及其用于治疗肝硬化的用途 |
| CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
| WO2020012357A1 (en) * | 2018-07-10 | 2020-01-16 | Integral Biosciences Pvt. Ltd. | Heterocyclic compounds and methods of use |
| LT3860998T (lt) | 2018-10-05 | 2024-06-25 | Annapurna Bio Inc. | Junginiai ir kompozicijos, skirti gydyti būkles, susijusias su apj receptoriaus aktyvumu |
| CN115052663B (zh) | 2020-01-08 | 2026-06-09 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| EP4182323B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine amino derivatives as alk5 inhibitors |
| EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| PT4182308T (pt) | 2020-07-15 | 2024-12-04 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| CA3232178A1 (en) | 2021-09-21 | 2023-03-30 | Daniela PIZZIRANI | Pyridazinyl amino derivatives as alk5 inhibitors |
| US20250270215A1 (en) | 2022-04-27 | 2025-08-28 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563001A1 (en) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazole compounds, their preparation and use |
| WO2001018000A1 (en) * | 1999-09-07 | 2001-03-15 | Merck Sharp & Dohme Limited | Imidazo-pyridine derivatives as ligands for gaba receptors |
| WO2004013138A2 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | Imidazo`1,2-a!pyridines |
| WO2008006583A1 (en) * | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023246A1 (en) * | 2003-09-04 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
| KR101229647B1 (ko) * | 2004-09-03 | 2013-02-05 | 메르크 세로노 에스.에이. | 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도 |
| BRPI0718266A2 (pt) * | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
-
2009
- 2009-04-27 EP EP09738114A patent/EP2307402B1/en not_active Not-in-force
- 2009-04-27 JP JP2011506677A patent/JP5507543B2/ja not_active Expired - Fee Related
- 2009-04-27 AU AU2009242145A patent/AU2009242145B2/en not_active Ceased
- 2009-04-27 ES ES09738114T patent/ES2399175T3/es active Active
- 2009-04-27 PT PT97381149T patent/PT2307402E/pt unknown
- 2009-04-27 CA CA2722131A patent/CA2722131A1/en not_active Abandoned
- 2009-04-27 WO PCT/EP2009/055066 patent/WO2009133070A1/en not_active Ceased
- 2009-04-27 CN CN200980115503.0A patent/CN102015691B/zh not_active Expired - Fee Related
- 2009-04-27 EA EA201001687A patent/EA201001687A1/ru unknown
- 2009-04-27 MX MX2010011867A patent/MX2010011867A/es active IP Right Grant
- 2009-04-27 BR BRPI0911490A patent/BRPI0911490A2/pt not_active IP Right Cessation
- 2009-04-27 US US12/935,405 patent/US9079897B2/en not_active Expired - Fee Related
- 2009-04-27 PL PL09738114T patent/PL2307402T3/pl unknown
- 2009-04-27 KR KR1020107024212A patent/KR20100130226A/ko not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0563001A1 (en) * | 1992-03-26 | 1993-09-29 | Neurosearch A/S | Imidazole compounds, their preparation and use |
| WO2001018000A1 (en) * | 1999-09-07 | 2001-03-15 | Merck Sharp & Dohme Limited | Imidazo-pyridine derivatives as ligands for gaba receptors |
| WO2004013138A2 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | Imidazo`1,2-a!pyridines |
| WO2008006583A1 (en) * | 2006-07-14 | 2008-01-17 | Novartis Ag | Pyrimidine derivatives as alk-5 inhibitors |
Non-Patent Citations (2)
| Title |
|---|
| A concise synthesis of quinazolinone TGF-b RI inhibitor through one-pot three-component Suzuki–Miyaura/etherification and imidate–amide rearrangement reactions;Hong-yu Li, et al.;《Tetrahedron》;20070826;第63卷;第11763-11770页 * |
| Synthesis and biological evaluation of novel 2,4,5-triaryl-1H-pyrazol-3(2H)-ones as inhibitors of ALK5;Xing Zhou Li, et al.;《Chinses Chemical letters 》;20081231;第19卷;第379-382页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102015691A (zh) | 2011-04-13 |
| PT2307402E (pt) | 2013-02-15 |
| KR20100130226A (ko) | 2010-12-10 |
| US9079897B2 (en) | 2015-07-14 |
| AU2009242145B2 (en) | 2012-07-05 |
| CA2722131A1 (en) | 2009-11-05 |
| EP2307402A1 (en) | 2011-04-13 |
| PL2307402T3 (pl) | 2013-05-31 |
| WO2009133070A1 (en) | 2009-11-05 |
| MX2010011867A (es) | 2010-11-26 |
| EP2307402B1 (en) | 2012-11-07 |
| US20110060004A1 (en) | 2011-03-10 |
| EA201001687A1 (ru) | 2011-06-30 |
| BRPI0911490A2 (pt) | 2016-01-05 |
| JP5507543B2 (ja) | 2014-05-28 |
| ES2399175T3 (es) | 2013-03-26 |
| AU2009242145A1 (en) | 2009-11-05 |
| JP2011518856A (ja) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102015691A (zh) | 作为活化素样受体激酶(alk4或alk5)抑制剂的咪唑并吡啶衍生物 | |
| ES2393430T3 (es) | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK | |
| ES2442930T3 (es) | Pirimidinas como inhibidores de cinasas | |
| ES2393932T3 (es) | Derivados de Pirimidina como inhibidores de ALK-5 | |
| JP5090528B2 (ja) | ALK4またはALK5が介在する疾患を処置するための2、3、7位置換イミダゾ[1,2−b]ピリダジン類 | |
| JP5566909B2 (ja) | ピリジン誘導体 | |
| JP2010508315A (ja) | 抗炎症剤としてのヘテロ環式化合物 | |
| EP1878733A1 (en) | Pyrimidine derivatives as ALK-5 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Basel Applicant after: Novartis Ag Address before: Basel Applicant before: Novartis AG |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140108 Termination date: 20170427 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |